Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CEBPA-51||MTL-CEBPA|NOV340 SMARTICLES||CEBPA-51 is a small activating RNA that induces expression of CEBPA mRNA and protein, which subsequently leads to upregulation of albumin, and thereby potentially inhibiting cell growth (PMID: 28882451).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||hepatocellular carcinoma||not applicable||CEBPA-51||Preclinical - Cell culture||Actionable||In a preclinical study, CEBPA-51 treatment resulted in induced expression of CEBPA mRNA and inhibited proliferation of hepatocellular carcinoma cells in culture (PMID: 28882451).||28882451|
|Unknown unknown||hepatocellular carcinoma||not applicable||CEBPA-51||Phase I||Actionable||In a Phase I trial, CEBPA-51 treatment resulted in increased Cebpa expression in WBC, stable disease over 4 months in 40% (4/10) of patients with hepatocellular carcinoma, with 1 patient achieved partial response for 18 months (J Clin Oncol, 36(no. 15_suppl), May 2018, 2509-2509; NCT02716012).||detail...|
|Unknown unknown||Advanced Solid Tumor||not applicable||CEBPA-51||Phase I||Actionable||In a Phase I trial, CEBPA-51 treatment demonstrated safety and preliminary efficacy, resulted in increased Cebpa expression in WBC in patients with advanced solid tumors, including hepatocellular carcinoma, colorectal, and fibrolamellar cancer (J Clin Oncol, 36(no. 15_suppl), May 2018, 2509-2509; NCT02716012).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|